Coronary Artery Disease (CAD)ILUMINANCT07864025
Identification of Lesion Characteristics in Coronary Plaques Using Multimodality Intravascular Imaging and Novel Photon-counting CT in Stable Angina
An observational study of Coronary Artery Disease (CAD) and Stable Angina Pectoris, run by Queen Mary University of London at 1 site in United Kingdom.
Trial summary
Coronary artery disease, caused by the furring up of the heart arteries by atherosclerosis, is a major cause of death in the UK. Despite existing therapies, adverse cardiovascular events remains high, especially in patients who have already had a heart attack, as some of these patients have aggressive atherosclerotic… Read more about this study
- Who is it for?
- Ages 18 to 79 years
- Conditions the study is for
- Coronary Artery Disease (CAD), Stable Angina Pectoris, Ischaemic Heart Disease (IHD)
- What is being tested?
- observational study
- How many people
- 70 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 19 Aug 2026to 3 Apr 2029
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 79 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with a chronic coronary syndrome
Who may be able to join
- Able and willing to give informed consent
- Between ages 18-79
- Patients with a stable coronary syndrome that had recent PC-CTA showing at least one lesion requiring further evaluation with intravascular imaging or fractional flow reserve and is considered suitable for PCI under IVUS guidance
Who cannot join
- Unable to or unwilling to give informed consent
- Age >80 years
- Recent acute coronary syndrome within < 3 months
- Renal failure (eGFR <60ml/min/1.73m²)
- History of previous coronary artery bypass surgery
- Decompensated heart failure, or left ventricular ejection fraction ≤30%
Show all 13Show fewer
- Previous heart transplantation
- Intravenous contrast allergy
- Unable to receive treatment with aspirin, heparin, or thienopyridines
- Anticipated life expectancy <1 year
- Pregnancy
- Patient that requires surgical revascularisation
- Extensive coronary artery disease (i.e. multiple chronic total occlusions) or tortuous coronary anatomy that does not allow assessment of the coronary arteries with NIRS-IVUS imaging
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Christos V Bourantas, MD PhD contact
United Kingdom1 site, 1 recruiting
- Recruiting
William Harvey Research Institute, Barts and The London, Queen Mary University of London
London
About this study
Official title: Next Generation Coronary Plaque Characterisation and Computation of Flow Patterns: Photon-Counting Computed Tomography Coronary Angiography Versus State-of-the-Art Multimodality Intravascular Imaging
Coronary artery disease, caused by the furring up of the heart arteries by atherosclerosis, is a major cause of death in the UK. Despite existing therapies, adverse cardiovascular events remains high, especially in patients who have already had a heart attack, as some of these patients have aggressive atherosclerotic disease. If we could identify these vulnerable patients, then in wider clinical practice in the future we might be able to treat them better with new therapies that can otherwise be expensive or come with a risk of side-effects. Traditionally, the assessment of atherosclerotic disease and the identification of the plaques that will cause heart attacks is performed using invasive imaging - imaging taken by passing a wire into the arteries of the heart that has a camera on its tip. Invasive imaging, however, can be used only in patients with symptoms and has risks. Photon counting (PC) CT is a new CT system that has image quality comparable to invasive imaging and can be used in the community to examine individuals with stable angina symptoms. In this study we aim to compare how well PC-CT detects high-risk plaques compared with invasive imaging and in due course develop a platform that will expedite the analysis of CT images to allow its broad use in the clinical practice.
- Being tested
- observational study
- Keywords
- Photon-counting CT, Coronary plaque characterization, Lipid-rich plaque, Intravascular ultrasound, Near-infrared spectroscopy, Vulnerable plaque, Coronary Artery Disease (CAD)
- Medical subject headings
- Coronary Artery Disease, Angina, Stable
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
observational studyOther
Observation study comparing Photon-counting CT with intravascular coronary imaging in patients with chronic coronary syndrome
| Study group | Role | What they receive |
|---|---|---|
| Patients with Chronic Coronary Syndrome | Not described Receives: Other: observational study |
What is being measured
The primary outcome is the main question the study is designed to answer.
Compare the efficacy of PC-CTA and of conventional CTA in assessing the percent atheroma volume (PAV) using the output of the NIRS-IVUS analysis as the reference standard
Measured: After each patient has had coronary angiography
Secondary outcomes (2)
Identify the optimal reconstruction method of PC-CTA data for measuring the PAV in the studied segment using the NIRS-IVUS estimations as the reference standard.
Measured: After each patient has had coronary angiography.
Compare the accuracy of PC-CTA and conventional CTA in measuring flow patterns.
Measured: After each patient has had coronary angiography.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Oct 2026
- Study start19 Aug 2026
- Primary completion3 Apr 2029 (estimated)
- Study completion3 Apr 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Coronary Artery Disease (CAD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 70 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Queen Mary University of London
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Christos V Bourantas, MD PhD, Principal investigator, Barts Health NHS Trust and Queen Mary University of London
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07864025
- Sponsor's protocol ID
- 367063
- Other IDs
- FS/CRTF/25/24845
- Acronym
- ILUMINA
- Status last verified
- Oct 2026
- First submitted
- 25 Sep 2026
- Last updated
- 7 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Sakai K, Shin D, Singh M, Malik S, Dakroub A, Sami Z, Weber J, Cao JJ, Parikh R, Chen L, Sosa F, Cohen DJ, Moses JW, Shlofmitz RA, Collet C, Shlofmitz E, Jeremias A, Khalique OK, Ali ZA. Diagnostic Performance and Clinical Impact of Photon-Counting Detector Computed Tomography in Coronary Artery Disease. J Am Coll Cardiol. 2025 Feb 4;85(4):339-348. doi: 10.1016/j.jacc.2024.10.069. Epub 2024 Oct 28.
PubMed 39466216Ramasamy A, Hamid A Khan A, Cooper J, Simon J, Maurovich-Horvat P, Bajaj R, Kitslaar P, Amersey R, Jain A, Deaner A, Reiber JH, Moon JC, Dijkstra J, Serruys PW, Mathur A, Baumbach A, Torii R, Pugliese F, Bourantas CV. Implications of computed tomography reconstruction algorithms on coronary atheroma quantification: Comparison with intravascular ultrasound. J Cardiovasc Comput Tomogr. 2023 Jan-Feb;17(1):43-51. doi: 10.1016/j.jcct.2022.09.004. Epub 2022 Sep 21.
PubMed 36270952Ramasamy A, Parasa R, Sokooti H, Zhang X, Tanboga IH, Kitslaar P, Broersen A, Rathod KS, Amersey R, Jain A, Ozkor M, Reiber JHC, Dijkstra J, Serruys PW, Moon JC, Mathur A, Torii R, Pugliese F, Baumbach A, Bourantas CV. Computed tomography versus near-infrared spectroscopy for the assessment of coronary atherosclerosis. EuroIntervention. 2024 Dec 2;20(23):e1465-e1475. doi: 10.4244/EIJ-D-24-00096.
PubMed 39618266Ramasamy A, Pugliese F, Tanboga IH, Kitslaar P, Dijkstra J, Mathur A, Torii R, Moon JC, Baumbach A, Bourantas CV. Head-to-Head Comparison of Near-Infrared Spectroscopy-Intravascular Ultrasound and Coronary Computed Tomography Angiography in Assessing Atheroma Characteristics. JACC Cardiovasc Imaging. 2024 Dec;17(12):1507-1510. doi: 10.1016/j.jcmg.2024.07.005. Epub 2024 Sep 11. No abstract available.
PubMed 39269412
Study at a glance
From the registry record, last updated by the sponsor on 7 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Next Generation Coronary Plaque Characterisation and Computation of Flow Patterns: Photon-Counting Computed Tomography Coronary Angiography Versus State-of-the-Art Multimodality Intravascular Imaging
- ClinicalTrials.gov ID
- NCT07864025
- Acronym / sponsor ID
- ILUMINA / 367063
- Keywords
- Photon-counting CT, Coronary plaque characterization, Lipid-rich plaque, Intravascular ultrasound, Near-infrared spectroscopy, Vulnerable plaque, Coronary Artery Disease (CAD)
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 70 participants (estimated)
- Lead sponsor
- Queen Mary University of LondonUniversity, hospital or other
- Study start
- 19 Aug 2026 (actual)
- Primary completion
- 3 Apr 2029 (estimated)
- Study completion
- 3 Apr 2029 (estimated)
- First posted
- 7 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Coronary artery disease, caused by the furring up of the heart arteries by atherosclerosis, is a major cause of death in the UK. Despite existing therapies, adverse cardiovascular events remains high, especially in patients who have already had a heart attack, as some of these patients have aggressive atherosclerotic disease. If we could identify these vulnerable patients, then in wider clinical practice in the future we might be able to treat them better with new therapies that can otherwise be expensive or come with a risk of side-effects. Traditionally, the assessment of atherosclerotic disease and the identification of the plaques that will cause heart attacks is performed using invasive imaging - imaging taken by passing a wire into the arteries of the heart that has a camera on its tip. Invasive imaging, however, can be used only in patients with symptoms and has risks. Photon counting (PC) CT is a new CT system that has image quality comparable to invasive imaging and can be used in the community to examine individuals with stable angina symptoms. In this study we aim to compare how well PC-CT detects high-risk plaques compared with invasive imaging and in due course develop a platform that will expedite the analysis of CT images to allow its broad use in the clinical practice.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients with Chronic Coronary Syndrome | – | Other: observational study |
Who may qualify
- Ages
- 18 to 79 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with a chronic coronary syndrome
Key inclusion criteria (3 listed)
- Able and willing to give informed consent
- Between ages 18-79
- Patients with a stable coronary syndrome that had recent PC-CTA showing at least one lesion requiring further evaluation with intravascular imaging or fractional flow reserve and is considered suitable for PCI under IVUS guidance
Key exclusion criteria (13 listed)
- Unable to or unwilling to give informed consent
- Age >80 years
- Recent acute coronary syndrome within < 3 months
- Renal failure (eGFR <60ml/min/1.73m²)
- History of previous coronary artery bypass surgery
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| observational studyObservation study comparing Photon-counting CT with intravascular coronary imaging in patients with chronic coronary syndrome | Other | Patients with Chronic Coronary Syndrome |
Primary outcome
Compare the efficacy of PC-CTA and of conventional CTA in assessing the percent atheroma volume (PAV) using the output of the NIRS-IVUS analysis as the reference standard
Time frame: After each patient has had coronary angiography
2 secondary outcomes
Identify the optimal reconstruction method of PC-CTA data for measuring the PAV in the studied segment using the NIRS-IVUS estimations as the reference standard.
Time frame: After each patient has had coronary angiography.
Compare the accuracy of PC-CTA and conventional CTA in measuring flow patterns.
Time frame: After each patient has had coronary angiography.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Oct 2026.
- Background: PubMed 39466216Sakai K, Shin D, Singh M, Malik S, Dakroub A, Sami Z, Weber J, Cao JJ, Parikh R, Chen L, Sosa F, Cohen DJ, Moses JW, Shlofmitz RA, Collet C, Shlofmitz E, Jeremias A, Khalique OK, Ali ZA. Diagnostic Performance and Clinical Impact of Photon-Counting Detector Computed Tomography in Coronary Artery Disease. J Am Coll Cardiol. 2025 Feb 4;85(4):339-348. doi: 10.1016/j.jacc.2024.10.069. Epub 2024 Oct 28.
- Background: PubMed 36270952Ramasamy A, Hamid A Khan A, Cooper J, Simon J, Maurovich-Horvat P, Bajaj R, Kitslaar P, Amersey R, Jain A, Deaner A, Reiber JH, Moon JC, Dijkstra J, Serruys PW, Mathur A, Baumbach A, Torii R, Pugliese F, Bourantas CV. Implications of computed tomography reconstruction algorithms on coronary atheroma quantification: Comparison with intravascular ultrasound. J Cardiovasc Comput Tomogr. 2023 Jan-Feb;17(1):43-51. doi: 10.1016/j.jcct.2022.09.004. Epub 2022 Sep 21.
- Background: PubMed 39618266Ramasamy A, Parasa R, Sokooti H, Zhang X, Tanboga IH, Kitslaar P, Broersen A, Rathod KS, Amersey R, Jain A, Ozkor M, Reiber JHC, Dijkstra J, Serruys PW, Moon JC, Mathur A, Torii R, Pugliese F, Baumbach A, Bourantas CV. Computed tomography versus near-infrared spectroscopy for the assessment of coronary atherosclerosis. EuroIntervention. 2024 Dec 2;20(23):e1465-e1475. doi: 10.4244/EIJ-D-24-00096.
- Background: PubMed 39269412Ramasamy A, Pugliese F, Tanboga IH, Kitslaar P, Dijkstra J, Mathur A, Torii R, Moon JC, Baumbach A, Bourantas CV. Head-to-Head Comparison of Near-Infrared Spectroscopy-Intravascular Ultrasound and Coronary Computed Tomography Angiography in Assessing Atheroma Characteristics. JACC Cardiovasc Imaging. 2024 Dec;17(12):1507-1510. doi: 10.1016/j.jcmg.2024.07.005. Epub 2024 Sep 11. No abstract available.
- Individual participant dataSharing planned: Undecided
Related trials for Coronary Artery Disease (CAD)
Not yet recruitingPhase 1/2
EDIT-401 in Adults Who Require Additional Lowering of Low-Density Lipoprotein Cholesterol (LDL-C)
Heterozygous Familial Hypercholesterolemia (HeFH)
Active, not recruitingPhase 3
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events
Coronary Artery Disease
Active, not recruiting
Troponin in Acute Chest Pain to Risk Stratify and Guide EffecTive Use of Computed Tomography Coronary Angiography
Coronary Artery Disease
Recruiting
A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Understanding and Management of Coronary Calcium (The Optimal Trial)
Cardiovascular Diseases, Myocardial Ischemia
Active, not recruitingPhase 4
Comparison of Moderate-Intensity Statin Plus Ezetimibe vs. High-Intensity Statin for Coronary Plaque Stabilization
Coronary Artery Disease, Atherosclerosis of Coronary Artery
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Christos V Bourantas, MD PhD contact
Christos V Bourantas, MD PhD principal investigator
Barts Health NHS Trust and Queen Mary University of London
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Coronary Artery Disease (CAD) and Stable Angina Pectoris, run by Queen Mary University of London at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 7 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ameer Hamid A Khan, MBBS BSc MSc (447780356028, a.h.a.khan@qmul.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Compare the efficacy of PC-CTA and of conventional CTA in assessing the percent atheroma volume (PAV) using the output of the NIRS-IVUS analysis as the reference standard (time frame: After each patient has had coronary angiography). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07864025, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Oct 2026.